Jade Biosciences, Inc. (JBIO)
16.57
+0.17
(+1.04%)
USD |
NASDAQ |
Nov 11, 16:00
16.57
0.00 (0.00%)
After-Hours: 17:43
Jade Biosciences Enterprise Value : 581.74M for Nov. 10, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 10, 2026 | 581.74M |
| November 09, 2026 | 530.90M |
| November 06, 2026 | 497.22M |
| November 05, 2026 | 435.57M |
| November 04, 2026 | 495.31M |
| November 03, 2026 | 465.44M |
| November 02, 2026 | 424.76M |
| October 30, 2026 | 433.02M |
| October 29, 2026 | 444.46M |
| October 28, 2026 | 466.71M |
| October 27, 2026 | 476.24M |
| October 26, 2026 | 460.99M |
| October 23, 2026 | 466.71M |
| October 22, 2026 | 487.05M |
| October 21, 2026 | 501.03M |
| October 20, 2026 | 483.87M |
| October 19, 2026 | 418.41M |
| October 16, 2026 | 395.53M |
| October 15, 2026 | 413.96M |
| October 14, 2026 | 393.62M |
| October 13, 2026 | 392.35M |
| October 12, 2026 | 429.21M |
| October 09, 2026 | 454.00M |
| October 08, 2026 | 438.74M |
| October 07, 2026 | 414.59M |
| Date | Value |
|---|---|
| October 06, 2026 | 391.71M |
| October 05, 2026 | 433.66M |
| October 02, 2026 | 436.84M |
| October 01, 2026 | 414.59M |
| September 30, 2026 | 432.39M |
| September 29, 2026 | 440.65M |
| September 28, 2026 | 451.46M |
| September 25, 2026 | 455.90M |
| September 24, 2026 | 475.61M |
| September 23, 2026 | 474.34M |
| September 22, 2026 | 604.63M |
| September 21, 2026 | 603.35M |
| September 18, 2026 | 616.07M |
| September 17, 2026 | 628.78M |
| September 16, 2026 | 597.63M |
| September 15, 2026 | 644.03M |
| September 14, 2026 | 694.87M |
| September 11, 2026 | 676.44M |
| September 10, 2026 | 755.89M |
| September 09, 2026 | 750.80M |
| September 08, 2026 | 775.59M |
| September 04, 2026 | 804.19M |
| September 03, 2026 | 801.01M |
| September 02, 2026 | 899.53M |
| September 01, 2026 | 875.37M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.254B |
| Alnylam Pharmaceuticals, Inc. | 19.71B |
| Anika Therapeutics, Inc. | 161.61M |
| Savara, Inc. | 911.95M |
| Vericel Corp. | 2.935B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.76M |
| Total Expenses (Quarterly) | 55.76M |
| EPS Diluted (Quarterly) | -0.7569 |
| Earnings Yield | -15.77% |
| Normalized Earnings Yield | -15.77 |